Strategic Integration of Electronic Quality Management Systems with Quality Risk Management: Advancing Pharmaceutical Compliance and Operational Excellence
The pharmaceutical sector requires strong and flexible quality systems to achieve operational excellence and regulatory compliance. Integrating Quality Risk Management (QRM) frameworks with Electronic Quality Management Systems (EQMS) provides a transformative approach to quality management across the pharmaceutical value chain. This paper investigates how EQMS and QRM can work together to promote proactive compliance, reduce process variability, and foster a culture of continuous improvement. While QRM offers a systematic process for identifying, evaluating, and managing quality risks throughout the product lifecycle, EQMS technologies provide real-time data collection, optimized documentation, automated workflows, and streamlined regulatory reporting. The integration of these systems enhances risk-based decision- making by addressing deviations, non-conformances, and change controls through analytics, trend analysis, and predictive modeling. Current industry practices, regulatory requirements from organizations such as the FDA and EMA, and technological developments that facilitate this integration, such as cloud-based EQMS systems and AI-enabled risk assessment tools, are critically assessed in this article. To demonstrate how integrated systems have facilitated faster time-to-market, reduced compliance gaps, and improved audit readiness, case studies and implementation models are examined. Additional considerations include system validation, user acceptance, and data integrity. Ultimately, EQMS and QRM integration represents a shift from reactive to proactive quality management, in line with ICH Q9 and ICH Q10 principles, positioning pharmaceutical firms to succeed in an increasingly complex and competitive regulatory environment. For stakeholders aiming to enhance quality outcomes through risk-based governance and digital transformation, this evaluation provides a strategic framework.
Authors
- Shikha Baghel Chauhan (ORCID: https://orcid.org/0000-0002-1569-213X)
- Chirag Jain (ORCID: https://orcid.org/0000-0002-4300-0794)
- Indu Singh (ORCID: https://orcid.org/0000-0002-9038-4364)
- Radhakrishan Gaur
Institutions
- Amity University (IN)
Publication Details
- Journal
- Current Pharmaceutical Design
- Published
- 2026-03-11
- DOI
- https://doi.org/10.2174/0113816128430008251210175444
- Primary Topic
- Pharmaceutical Quality and Counterfeiting
- Type
- article
- Field-Weighted Citation Impact
- 0.00